The firm uses new building blocks to create proteins that impart specificity not possible with native proteins.
The company was founded by Avalon Ventures based on discoveries at The Scripps Research Institute in La Jolla, California.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze